摘要
中国国家食品药品监督管理局已批准4类核苷和核苷酸类药物（NAs）用于慢胜乙型肝炎患者（CHB）治疗。用这些药物可对CHB患者进行有效治疗，但常发生HBV对这些NAs耐药，导致治疗失败和疾病进展。本文综述了HBV对NAs的耐药机制，以及专家对耐药管理和预防的共识。
Currently, four nucleos（t）ide analogs （NAs） are approved by China＇s Food and Drug Administration to treat patients with chronic hepatitis B （CHB）. Unfortunately, hepatitis B virus （HBV） strains carrying mutations that confer drug resistance to these NAs are frequent, and the rate of CHB patients failing to respond to treatment is on the rise. Since drug-resistance is associated with liver disease progression, extensive research has been carried out to determine its underlying mechanisms. In this review, we discuss the molecular mechanisms of NA-resistance and their implications for patient management and development of effective HBV-targeted preventive strategies.
出处
《中华肝脏病杂志》
CAS
CSCD
北大核心
2013年第1期15-22,共8页
Chinese Journal of Hepatology
关键词
肝炎
乙型
慢性
抗药性
核昔和核苷酸类药物
管理
Hepatitis B, chronic
Drug resistance
Nucleoside and nueleotide analogs
Management
